Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands

Zhiqin Deng; Guangyu Zhu

doi:10.1016/j.cbpa.2023.102303

Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands

Zhiqin Deng, Guangyu Zhu^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

34 Citations (Scopus)

Abstract

The clinical application of Pt-based anticancer drugs has inspired the development of novel chemotherapeutic metallodrugs with improved efficacies. Pt(IV) prodrugs are one of the most promising successors of Pt(II) drugs and have displayed great anticancer performance. In particular, judicious modification of axial ligands endows Pt(IV) complexes with unique properties that enable them to overcome the limitations of conventional Pt(II) drugs. Herein, we summarize recent developments in Pt(IV) anticancer complexes, with a focus on their axial functionalization with other anticancer agents, immunotherapeutic agents, photosensitive ligands, peptides, and theranostic agents. We hope that this concise view of recently reported Pt(IV) coordination complexes will help researchers to design next-generation multi-functional anticancer agents based on a comprehensive Pt(IV) platform. © 2023 Elsevier Ltd

Original language	English
Article number	102303
Journal	Current Opinion in Chemical Biology
Volume	74
Online published	17 Apr 2023
DOIs	https://doi.org/10.1016/j.cbpa.2023.102303
Publication status	Published - Jun 2023

Funding

We thank the National Natural Science Foundation of China (Grant Nos. 22077108 and 22277103), the Hong Kong Research Grants Council (Grant Nos. CityU 11307419, 11303320, 11302221, and 11313222), and the Science Technology and Innovation Committee of Shenzhen Municipality (JCYJ20210324120004011) for funding support.

Research Keywords

Anticancer agent
Chemo-immunotherapy
Chemotherapy
Platinum drug
Pt(IV) prodrug

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access Output

10.1016/j.cbpa.2023.102303

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{fa6752a019ac4f6ab93432fb38603306,

title = "Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands",

abstract = "The clinical application of Pt-based anticancer drugs has inspired the development of novel chemotherapeutic metallodrugs with improved efficacies. Pt(IV) prodrugs are one of the most promising successors of Pt(II) drugs and have displayed great anticancer performance. In particular, judicious modification of axial ligands endows Pt(IV) complexes with unique properties that enable them to overcome the limitations of conventional Pt(II) drugs. Herein, we summarize recent developments in Pt(IV) anticancer complexes, with a focus on their axial functionalization with other anticancer agents, immunotherapeutic agents, photosensitive ligands, peptides, and theranostic agents. We hope that this concise view of recently reported Pt(IV) coordination complexes will help researchers to design next-generation multi-functional anticancer agents based on a comprehensive Pt(IV) platform. {\textcopyright} 2023 Elsevier Ltd",

keywords = "Anticancer agent, Chemo-immunotherapy, Chemotherapy, Platinum drug, Pt(IV) prodrug",

author = "Zhiqin Deng and Guangyu Zhu",

year = "2023",

month = jun,

doi = "10.1016/j.cbpa.2023.102303",

language = "English",

volume = "74",

journal = "Current Opinion in Chemical Biology",

issn = "1367-5931",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Beyond mere DNA damage

T2 - Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands

AU - Deng, Zhiqin

AU - Zhu, Guangyu

PY - 2023/6

Y1 - 2023/6

N2 - The clinical application of Pt-based anticancer drugs has inspired the development of novel chemotherapeutic metallodrugs with improved efficacies. Pt(IV) prodrugs are one of the most promising successors of Pt(II) drugs and have displayed great anticancer performance. In particular, judicious modification of axial ligands endows Pt(IV) complexes with unique properties that enable them to overcome the limitations of conventional Pt(II) drugs. Herein, we summarize recent developments in Pt(IV) anticancer complexes, with a focus on their axial functionalization with other anticancer agents, immunotherapeutic agents, photosensitive ligands, peptides, and theranostic agents. We hope that this concise view of recently reported Pt(IV) coordination complexes will help researchers to design next-generation multi-functional anticancer agents based on a comprehensive Pt(IV) platform. © 2023 Elsevier Ltd

AB - The clinical application of Pt-based anticancer drugs has inspired the development of novel chemotherapeutic metallodrugs with improved efficacies. Pt(IV) prodrugs are one of the most promising successors of Pt(II) drugs and have displayed great anticancer performance. In particular, judicious modification of axial ligands endows Pt(IV) complexes with unique properties that enable them to overcome the limitations of conventional Pt(II) drugs. Herein, we summarize recent developments in Pt(IV) anticancer complexes, with a focus on their axial functionalization with other anticancer agents, immunotherapeutic agents, photosensitive ligands, peptides, and theranostic agents. We hope that this concise view of recently reported Pt(IV) coordination complexes will help researchers to design next-generation multi-functional anticancer agents based on a comprehensive Pt(IV) platform. © 2023 Elsevier Ltd

KW - Anticancer agent

KW - Chemo-immunotherapy

KW - Chemotherapy

KW - Platinum drug

KW - Pt(IV) prodrug

UR - http://www.scopus.com/inward/record.url?scp=85152549112&partnerID=8YFLogxK

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85152549112&origin=recordpage

U2 - 10.1016/j.cbpa.2023.102303

DO - 10.1016/j.cbpa.2023.102303

M3 - RGC 21 - Publication in refereed journal

SN - 1367-5931

VL - 74

JO - Current Opinion in Chemical Biology

JF - Current Opinion in Chemical Biology

M1 - 102303

ER -

Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands

Abstract

Funding

Research Keywords

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

GRF: Synthesis and Anticancer Evaluation of Near-infrared-activatable Platinum Photooxidants

GRF: Development and Biological Evaluation of Ultrasound-activatable Platinum(IV) Anticancer Prodrugs

GRF: Photocaged Platinum Anticancer Prodrugs Targeting the Endoplasmic Reticulum to Conquer Drug Resistance

Cite this

Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands

Abstract

Funding

Research Keywords

UN SDGs

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Projects

GRF: Synthesis and Anticancer Evaluation of Near-infrared-activatable Platinum Photooxidants

GRF: Development and Biological Evaluation of Ultrasound-activatable Platinum(IV) Anticancer Prodrugs

GRF: Photocaged Platinum Anticancer Prodrugs Targeting the Endoplasmic Reticulum to Conquer Drug Resistance

Cite this